The global Biosimilars Market , valued at US$32.75 billion in 2024 stood at US$35.04 billion in 2025 and is projected to ...

Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in India and Canada within the next two years, a top executive told Reuters ...

Top largecap stocks that mutual funds bought in June included Asian Paints, Trent, Bajaj Finserv, Infosys, and Bharti Airtel, ...

Biocon aims to introduce generic versions of the obesity drug Wegovy in India and Canada by late 2026 or early 2027, ...

Biocon is set to launch generic versions of Wegovy in India and Canada, aiming for market entry by late 2026 or early 2027.

Biocon plans to introduce generic versions of the weight-loss drug Wegovy in India and Canada by 2027, according to CEO Siddharth Mittal.

Biocon plans to launch generic copies of Wegovy in India and Canada within two years, targeting a growing drug market ...

India's pharma and healthcare sector saw 57 deals worth $1.30 billion in the quarter ending June. This reflects a drop ...

Nifty rose above 25,100 and Sensex gained 76 points, recovering from earlier losses led by sectoral strength.Stock-Specific ...

Kiran Mazumdar-Shaw assessed the readiness of the Hebbagodi Metro Station with BMRCL officials, expressing enthusiasm for the ...

The US Food and Drug Administration approved, the first rapid-acting interchangeable biosimilar product, Kirsty (insulin ...

Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in India and Canada within the next two years ...